Search

everythinglearnresearchcommunity

for

Search:↓

More effective treatments are needed for alopecia areata, hidradenitis suppurativa, and vitiligo.

New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.

Methotrexate can temporarily suppress certain immune responses without killing immune cells, potentially helping treat autoimmune diseases.

Personalized acne treatments and new therapies show promise for better results.

The new chemotherapy combination of WP 631 and Epothilone B shows enhanced effectiveness against ovarian cancer but requires more research on its safety.

Methotrexate plus prednisolone had the fewest serious side effects.

Monilethrix has no effective treatment, but avoiding hair trauma helps manage it.

The combination of mitoxantrone, etoposide, and prednisolone is effective for treating relapsed lymphoma with manageable side effects.

MK-5108 is safe and shows potential against tumors, especially alone.

Emerging therapies like JAK inhibitors show promise for hair regrowth in alopecia areata.

Topical immunotherapy can help with severe hair loss, but results vary and need personalized, long-term treatment.

Drugmakers are optimistic about targeting the Wnt pathway for new treatments despite past challenges.

Mesotherapy can improve skin and hair health by using targeted injections.

Some moles can disappear naturally, maintenance therapy for Stage 1 mycosis fungoides may not be necessary, allergic skin reactions in children are rising, weekly methotrexate for psoriasis is more effective than daily, long-term finasteride use improves hair growth with few side effects, and petrolatum improves UV therapy for psoriasis.

Insurers opposed ASCO's recommendation for a single cancer care pathway program.

Trametinib can effectively treat severe kaposiform lymphangiomatosis when other treatments fail.

Some treatments worked for horse ringworm, but mass treatment should focus on stopping infection spread, not just hair regrowth.

Dermatological treatments can have significant side effects, including allergic reactions, sexual dysfunction, and increased cancer risk.

Adding dupilumab led to almost complete hair regrowth in a patient with alopecia areata who only partially responded to baricitinib.

Topical minoxidil showed promise for early male pattern baldness.

Radiotherapy was effective for treating a large scalp plaque of Bowen's disease when other treatments failed.

The choice between belimumab and anifrolumab for treating lupus depends on the patient's specific symptoms.

Biorregulatory therapy significantly improved the dog's health, reversing previous issues and eliminating the need for ongoing medication.

Sacituzumab tirumotecan shows promise in treating breast cancer with manageable side effects.

Leflunomide may reduce the risk of alopecia areata, while methotrexate, cyclosporine, and rituximab may increase it.

Including ineffective or unsafe doses in reviews can lead to misleading conclusions about alopecia areata treatments.

Immunosuppressive therapy helps manage autoimmune diseases but carries risks like infection and potential for malignancy.

Melasma treatment is difficult, but combination therapies and personalized plans show promise.